Details for New Drug Application (NDA): 215026
✉ Email this page to a colleague
The generic ingredient in DEFERASIROX is deferasirox. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 215026
Tradename: | DEFERASIROX |
Applicant: | Cipla |
Ingredient: | deferasirox |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 215026
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
DEFERASIROX | deferasirox | GRANULE;ORAL | 215026 | ANDA | Cipla USA Inc. | 69097-550 | 69097-550-53 | 30 PACKET in 1 CARTON (69097-550-53) / 1 GRANULE in 1 PACKET |
DEFERASIROX | deferasirox | GRANULE;ORAL | 215026 | ANDA | Cipla USA Inc. | 69097-560 | 69097-560-53 | 30 PACKET in 1 CARTON (69097-560-53) / 1 GRANULE in 1 PACKET |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULE;ORAL | Strength | 90MG | ||||
Approval Date: | Feb 23, 2022 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULE;ORAL | Strength | 180MG | ||||
Approval Date: | Feb 23, 2022 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | GRANULE;ORAL | Strength | 360MG | ||||
Approval Date: | Feb 23, 2022 | TE: | AB | RLD: | No |
Complete Access Available with Subscription